Doxofylline MR Granules

Product Overview

Doxofylline is a phosphodiesterase-inhibiting bronchodilator utilized in the management of chronic respiratory conditions, including asthma and COPD. It is a derivative of xanthine, just like theophylline. Its Modified Release (MR) granule form ensures sustained plasma levels, better compliance, and reduced dosing frequency compared to conventional formulations.

Product Name
Doxofylline Modified Release (MR) Granules
Strengths Available
65% (typically equivalent to 400 mg & 800 mg tablet formulations)
CAS No. / IUPAC Name
CAS: 69975-86-6; IUPAC: 7-(1,3-dioxolan-2-ylmethyl)-1,3-dimethylpurine-2,6-dione
Molecular Formula / Weight
C11H14N4O4 / ~266.25 g/mol
Identification
Validated HPLC / UV Spectrophotometry (USP/BP/EP compliant)
Release Type
Modified Release (MR) designed to ensure sustained plasma concentrations, reducing dosing frequency.
Applications
Formulation into modified-release tablets/capsules. Used in respiratory therapy: management of asthma & chronic obstructive pulmonary disease (COPD).
Storage Conditions
Store in a tightly closed container, away from direct light, moisture, and heat. Recommended storage at controlled room temperature.

Doxofylline MR Granules – Typical Composition

Component	Function
Doxofylline	Active Ingredient (Bronchodilator)
Hydroxypropyl Methylcellulose (HPMC) / Ethylcellulose	Sustained Release Matrix Former
Lactose Monohydrate / Mannitol	Diluent / Filler
Croscarmellose Sodium / Crospovidone	Disintegrant
Magnesium Stearate	Lubricant
Colloidal Silicon Dioxide	Glidant

Why Choose Granules from Salius Pharma?

Outsourcing DC Granules through a trusted partner like Salius Pharma can be a strategic decision to save both time and resources, without compromising on quality or compliance. Instead, partnering with Salius Pharma—a leading developer aligned with USFDA-approved and WHO-GMP-certified manufacturers in India—allows you to leverage high-quality products, seamless logistics, and professional support under one roof.

Key Advantages of Partnering with Salius Pharma

Cost-Efficient Setup
Avoid heavy capital investment in infrastructure and workforce.
Guaranteed Quality Assurance
Products are sourced only from certified facilities with validated processes.
Access to Advanced Technology
Benefit from the latest drug delivery systems without managing the tech in-house.
Accelerated Market Entry
Launch products faster and establish your brand in less time.
Custom Formulation Support
Flexibility to offer tailored pellet solutions as per your market needs.

Expected Delivery Time

We ensure prompt and reliable shipping worldwide. Delivery times may vary depending on destination, order volume, and regulatory requirements.

Place an Order or Request a Quote from Salius Pharma

Looking to source Doxofylline MR Granules or other high-quality pharmaceutical pellet formulations?
Whether you need Active Pharmaceutical Ingredients (APIs), excipients, or regulatory support, our team is ready to provide reliable, compliant, and cost-effective solutions tailored to your market needs.

Get in Touch

Email: export@saliuspharma.com
Call / WhatsApp: +91 84258 80640 / +91 84258 80643
Landline: +91 22 49700 601 / +91 22 44503 148
Corporate Office: 3104–3106, Plan S Business Park, Nerul MIDC Opp. Dr. D.Y. Patil Stadium, Navi Mumbai – 400706, Maharashtra, India

Confidentiality Notice

The contents of this page and any attachments are intended solely for the designated recipient(s) and may contain confidential and/or privileged information protected by law.

Any patented products are excluded from our offerings in regions where such patents are currently in force.

FAQs

Doxofylline MR granules are used to formulate modified release tablets or capsules for the management of asthma and chronic obstructive pulmonary disease (COPD). The MR form ensures sustained bronchodilation and helps maintain stable therapeutic levels over time.

MR granules provide a controlled and prolonged drug release, which reduces the frequency of dosing, ensures consistent therapeutic effects, and improves patient compliance compared to immediate-release formulations.

The granules can be formulated into tablets of 400 mg and 800 mg equivalent, and strengths can be customized based on market or regulatory requirements.

MR granules offer ease of processing, consistent quality, and compliance with USP/EP standards, enabling the production of high-quality, patient-friendly modified-release tablets or capsules.

Enquiry